Pacific Biosciences Of California (PACB) EBT (2010 - 2026)

Pacific Biosciences Of California has reported EBT for 17 years, with the latest figure at -$44.7 million in Q2 2026.

• On a quarterly basis, EBT fell 6.65% year-over-year to -$44.7 million in Q2 2026; TTM through Jun 2026 was -$130.6 million, a 75.19% increase from a year earlier, with the FY2025 full-year figure at -$546.1 million, down 76.41% from the prior year.
• EBT was -$44.7 million for Q2 2026 at Pacific Biosciences Of California, down from -$8.1 million in the prior quarter.
• The five-year high for EBT was $2.7 million in Q4 2024, with the low at -$426.4 million in Q1 2025.
• Average EBT over 5 years is -$85.6 million, with a median of -$74.2 million recorded in 2022.
• The sharpest annual moves came in 2024 and 2025: EBT jumped 103.25% in 2024, then tumbled 1594.94% in 2025.
• Over 5 years, EBT stood at -$84.4 million in 2022, then advanced by 1.95% to -$82.7 million in 2023, then surged by 103.25% to $2.7 million in 2024, then plunged by 1594.94% to -$40.2 million in 2025, then decreased by 11.24% to -$44.7 million in 2026.
• The last three EBT figures came in at -$44.7 million (Q2 2026), -$8.1 million (Q1 2026), and -$40.2 million (Q4 2025), per Business Quant data.